Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Biologic aging is associated with MS disability progression

Publish date:: March 1, 2019

Key clinical point: Telomere length, a marker of biologic aging, correlates with multiple sclerosis disability independent of chronological age.

Major finding: After adjusting for age, disease duration, and sex, every 0.2-unit decrease in telomere length was associated with a score increase of 0.27 on the Expanded Disability Status Scale.

Study details: A cohort study of 516 adults with multiple sclerosis or clinically isolated syndrome.

Disclosures: The study was funded by the National Multiple Sclerosis Society.

Citation:

Krysko KM et al. ACTRIMS Forum 2019, Abstract 289.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,